The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
